Videos

Michael J. Mauro, MD, provides a summary of a presentation at the 2024 Society of Hematologic Oncology Annual Meeting on the recent advancements in CML treatment and applying clinical evidence to cases that are advanced.

Mikkael A. Sekeres MD, MS, discusses when he decides to start therapy for anemia in patients with low-risk myelodysplastic syndromes.

Craig A. Portell, MD, previews his session on sequencing therapies in relapsed/refractory mantle cell lymphoma being presented at the 2024 Society of Hematologic Oncology Annual Meeting.

Reid Merryman, MD, discusses the role of minimal residual disease in lymphoma and his presentation on the topic at the 2024 Society of Hematologic Oncology Annual Meeting.

Partow Kebriaei, MD, discusses transplant in acute lymphoblastic leukemia.

Sonali M. Smith, MD, discusses how T-cell–directed therapies work in the context of indolent B-cell lymphoma.

Experts on lower-risk MDS discuss when to switch to a topoisomerase inhibitor versus going to a hypomethylating agent.

Jamie Koprivnikar, MD, and Solly Chedid, MD, discuss ways to continue to advance the treatment landscape for lower-risk MDS, particularly in managing anemia and improving quality of life for patients.

Sergio A. Giralt, MD, discusses the current indications for considering stem cell transplants in patients with myelodysplastic syndrome.

Stefan Barta, MD, discusses the heterogeneity of T-cell lymphoma, highlighting that a one-size-fits-all approach is ineffective and emphasizing the need for tailored treatment approaches.

Sangeetha Venugopal, MD, MS, discusses how measurable residual disease is used during the course of treatment of AML.

Medical specialists analyze the case of a 58-year-old man presenting to the emergency room with hematuria and abdominal pain, while considering the most recent clinical data to inform their treatment approach for renal cell carcinoma.

Oncology experts examine their patient population demographics and discuss the percentage of clear cell renal cell carcinoma patients who progress to receive third-line and subsequent lines of therapy.

Panelists discuss how chronic graft-versus-host disease manifests across multiple organ systems and the diagnostic criteria used to identify and assess its various presentations.

Jeff Sharman, MD, discusses the clinical implications for oncologists based on data from the ELEVATE-TN trial.

Sangeetha Venugopal, MD, MS, discusses the dynamic landscape of molecular targets in acute myeloid leukemia.

Christina Henson, MD, discusses how new guidelines for head and neck cancer imaging could change dynamics for physicians and patients.

Claire Saxton, MBA, discusses findings from a study looking at social toxicity in acute myeloid leukemia.

Anil Parwani, MD, PhD, discusses the use of artificial intelligence technology to enhance cancer diagnostics and treatment.

Julie Vose, MD, discusses the exciting developments across lymphomas.

Anil Parwani, MD, PhD, discusses how the use of artificial intelligence technology can be integrated into the current workflow of pathologists.

Elizabeth Franzmann, MD, discusses findings of a study exploring a novel method of testing recurrence of head and neck cancer.

Experts discuss factors influencing the choice between luspatercept and erythropoiesis-stimulating agents (ESAs) for initial anemia treatment, considerations for transitioning patients from ESAs to luspatercept, optimal timing for such transitions, and the clinical benefits of luspatercept dose titration as evidenced by real-world data presented at EHA 2024.

Clinicians discuss personalized approaches to initiating and adjusting luspatercept dosing, considering individual patient responses and tolerability, while also examining insights from the MAXILUS study, which explored starting treatment at the maximum approved dose.

Ira Zackon, MD, explains how clinicians can ensure clinical trial patient populations are more inclusive and minorities are better represented.

Renal cell carcinoma specialists continue analyzing the case of a 61-year-old patient with indolent metastatic clear cell RCC, evaluating available therapeutic options, discussing disease progression, and addressing recent changes in treatment guidelines.

Medical experts explore dose reduction strategies, alternative therapies, and clinical pearls for optimizing health outcomes in renal cell carcinoma patients treated with immune checkpoint inhibitor and tyrosine kinase inhibitor combinations.

Jamie Koprivnikar, MD, provides key takeaways for optimizing anemia management in patients with lower-risk MDS, highlighting unmet needs in treating anemia and improving patient outcomes.

An expert on the treatment of patients with myelodysplastic syndromes provides clinical insights on dosing practices and considerations for luspatercept.